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Abstract
Background: The relevance of regular moderate to intense exercise for ameliorating psychomotor symptoms in
persons with multiple sclerosis (pwMS) is becoming increasingly evident. Over the last two decades, emerging
evidence from clinical studies and animal models indicate immune regulatory mechanisms in both periphery and
the central nervous system that may underlie these beneficial effects. The integrity of the blood-brain barrier as the
main structural interface between periphery and brain seems to play an important role in MS. Reducing the
secretion of proteolytic matrix metalloproteinases (MMP), i.e. MMP-2, as disruptors of blood-brain barrier integrity
could have profound implications for MS.
Methods: In this two-armed randomized controlled trial 64 participants with relapsing-remitting MS (RRMS) (EDSS
0–4.0) will be allocated to either an intervention group or a passive wait list control group. The intervention group
will perform 60 min of combined functional resistance and endurance exercises 3x per week over a period of 12
weeks in a community-based and publicly available setting. Changes in serum concentration of MMP-2 will be the
primary outcome. Secondary outcomes are numbers of immune cell subsets, soluble (anti-) inflammatory factors,
physical capacity, cognitive performance, physical activity behavior, gait performance, and patient-reported
outcomes. All outcome measures will be assessed at baseline and after week 12 with an additional blood sampling
before, during and immediately after a single training session in week 6.
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Discussion: To our knowledge, this will be the first RCT to investigate both the acute and chronic effects of a
community-based intense functional resistance and endurance exercise regimen in persons with RRMS. Combining
analysis of biological and cognitive or psychological outcomes may provide a better understanding of the MS-
specific symptomology.
Trial registration: DRKS00017091; 05th of April, 2019; International Clinical Trials Registry Platform.
Keywords: Relapsing-remitting multiple sclerosis, Matrix metalloproteinase-2, Functional exercise, Immune
homeostasis, Kynurenine pathway, Inflammation
Background
Accumulating evidence over the past two decades under-
lines the role of a dysregulated immune system in the
pathophysiology and progression of multiple sclerosis
(MS) [1]. The broad immunoregulatory effects of regular
exercise is becoming more evident and is now recom-
mended as an adjunct therapy for people suffering from
chronic (neuro-)inflammatory diseases, such as MS [2–4].
Evidence-informed physical activity guidelines for persons
with MS (pwMS) have already been developed [5], but less
than 30% of pwMS meet the recommended guidelines for
moderate to vigorous exercise [6]. A perturbed peripheral
immune homeostasis indicated by the imbalance of T cell
subsets seems to be a major disease-specific characteristic
[7, 8]. Interestingly, there might be a proposed intensity-
dependent effect of physical exercise on regulatory T cell
homeostasis by increasing their cell counts and anti-
inflammatory potential [9].
Moreover, there are emerging biopsychosocial models
that link a dysregulated immune system, i.e. proinflam-
matory cytokines, to cognitive impairment and fatigue
which represent the most relevant symptoms for pwMS
[10, 11]. It was shown in different patient cohorts that
exercise might be a promising therapeutic approach to
improve cognitive performance [12–14] with both resis-
tance and endurance exercise being feasible and beneficial
for pwMS [15, 16].
The classification of MS as an autoimmune neuroinflam-
matory disease favored research to elucidate how activated
peripheral (autoreactive) immune cells or neurotoxic sub-
stances invade into the central nervous system (CNS) and
contribute to disease progression. Increased secretion of
proteolytic matrix metalloproteinases (MMP), i.e. MMP-2,
as modulators of blood-brain barrier (BBB) integrity seems
to have profound implications for MS [17–19]. We have
shown that, in contrast to moderate continuous training,
high intensity interval training over a period of 3 weeks re-
duces serum levels of MMP-2 [20]. Further, a recent sys-
tematic review of human intervention studies concludes
that exercise training positively modulates BBB permeabi-
lity markers in pwMS [21].
Acute intense exercise provokes a transient inflamma-
tory state and enzymatic conversion of tryptophan
(TRP) to kynurenine (KYN) and further KYN metabo-
lites ( [22], Joisten 2019 accepted). It is assumed that
exercise-induced activation of immune cells plays a signifi-
cant role in this process. KYN may has potent immune
regulatory characteristics by inhibiting the activation of
pro-inflammatory immune cells while promoting differen-
tiation of regulatory T cells [23, 24]. However, chronic
synthesis of KYN through long term peripheral immune
dysregulation seems to be involved into the pathophysi-
ology of MS [25, 26]. By passing the BBB, KYN can be me-
tabolized into neurotoxic quinolinic acid (QUIN) by
locally activated immune cells. Exercise-induced conver-
sion of KYN to kynurenic acid (KYNA) and NAD+ may
decrease translocation of KYN into CNS, thereby limiting
kynurenine-associated neurotoxicity [27, 28].
In a review discussing the relevance of immune regula-
tory treatments in MS, Dendrou et al. [1] recommend
multimodal targeting of peripheral and CNS-intrinsic in-
flammation in early disease stages. Further, Riemensch-
neider et al. [29] propose to conduct exercise treatments
in the early disease stage to promote evidence-based
clinical integration for a “window of opportunity” in MS
exercise therapy.
Since opportunities for early-phase MS rehabilitation in
rehabilitation centers are rare and limited to some weeks
per year, the overall objective of this study is to investigate
the chronic effects of a community-based 12-week exer-
cise training in a publicly available setting in pwMS with
light symptomatology. By correlating the assessed cogni-
tive capacity and patient-reported outcomes like anxiety/
depression and fatigue with immune-related biomarkers
and cell populations, existing hypothetical biopsychosocial
models in pwMS [10] will be addressed in the context of
exercise neuroimmunology.
Methods/design
In this study, a two-armed single-blind randomized con-
trolled trial design will be applied. Prior to (T0) and 48 h
after the intervention period (T2), an assessment of cardio-
vascular fitness, muscular strength, cognitive performance,
gait performance and patient-reported outcomes (depres-
sion and anxiety, fatigue, quality of life, sleep quality, phys-
ical activity behavior, social integration) will be conducted.
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Blood samples at rest will be taken at T0, midpoint (T1)
and T2. To investigate acute changes of BBB markers, im-
mune homeostasis, (anti-) inflammatory factors as well as
TRP metabolites, there will be an additional assessment of
blood samples before (T1), during (T1.1) and after (T1.2) a
training session with the resting values at T1 being further
used for midpoint follow-up. Blood samples from the con-
trol group at T1 will be assessed without further measure-
ments at T1.1 and T1.2. To control for the participants’
daily activity level, the participants will be asked to adhere
to a 7-day actigraphic measurement on three time-points
(T0,T1,T2).
All assessments and blood-sampling will be conducted at
the German Sport University Cologne, except for the blood
samples at T1,T1.1,T1.2 in the intervention group. This blood
sampling will be done by a physician at the fitness center.
Due to the nature of the trial, participants could not
be blinded to group allocation. Assessors taking out-
come measures post intervention will be blinded to
group allocation. The training sessions will be supervised
by MS experienced exercise scientists. The trainers will
not be involved in the post assessment to keep blinding.
Participants and recruitment
A total of 64 persons with definite diagnosis of relapsing-
remitting multiple sclerosis (RRMS) (revised McDonald cri-
teria [30]) will be recruited through announcements at the
German Sports University Cologne, the Deutsche Multiple
Sklerose Gesellschaft (DMSG, Ortsvereinigung Köln und
Umgebung e.V.), and local MS clinics. The participants will
be screened for eligibility by the study supervisor with fur-
ther key inclusion criteria of an Expanded Disability Status
Scale (EDSS) [31] score between 0 and 4.0.
Eligibility
Prior to inclusion, participants will be screened for exclu-
sion criteria and general sports capability (see Table 1). If
eligible, the participant will be asked to provide written in-
formed consent. After stratification, the participants will
be randomized to either the intervention group or a
passive waitlist control group.
Randomization
Participants will be randomly allocated (1:1) to either the
intervention group or a passive waitlist control group. A
concealed randomization approach will be conducted by
an independent employee using “Randomization-In-Treat-
ment-Arms” software (RITA, Evident, Germany) that fol-
lows the minimization procedure [32]. To ensure equal
allocation of subgroups of participants to both experimen-
tal conditions, following stratification factors will be used:
age, lean body mass, disease severity (EDSS), intake of im-
mune regulatory medication, the sum of the hypothetical
one-repetition maximums (h1RMsum) and peak power
output (Wattmax).
Study intervention
Experimental intervention group
All training sessions will take place in a publicly avail-
able fitness center in Cologne, Germany. Participants of
the intervention group will conduct three training
sessions per week for a period of 12 weeks. In groups of
maximal ten, the participants will perform endurance
and resistance exercises for 60 min with 30 min of
resistance exercises and 20 min of endurance/ strength
endurance exercises. Each session will be supervised by
MS experienced exercise scientists. To guarantee
appropriate muscle activation, a 10-min warm-up with
light aerobic activity and mobilization will be applied.
An additional table shows the exercise program in
more detail (see Additional file 1). To avoid difficulties
with fixed-time training sessions and to improve adher-
ence, participants will be able to choose between differ-
ent weekdays and time slots.
Table 1 Detailed list for eligibility screening
Inclusion criteria Exclusion criteria
♦ Age: 18–45 years ♦ Acute episode or significant exacerbation of multiple sclerosis
symptoms during intervention
♦ EDSS: 0–4.0 (inclusive)
♦ Approved sport capability
♦ Approved RRMS ♦ Cardiac preload
♦ Orthopaedic diseases limiting the execution of the intervention
and assessments
♦ Problems in understanding (not German-speaking)
♦ Concomitant disease states (internistic or neurological) affecting
study outcomes
♦ Cancer diseases under treatment of chemotherapy or radiation
therapy
♦ Pregnant or breast-feeding women
EDSS Expanded Disability Status Scale, RRMS Relapsing-remitting multiple sclerosis
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A progressive periodization with step by step learning
will be applied during the first 2 weeks of the interven-
tion to guarantee precise movement execution of free
weight resistance exercises. Thereafter, the participants
will increase the load in consultation with the trainer.
The endurance / strength-endurance part comprises al-
ternating short ergometer exercises, body weight exercises
and exercises with small, functional devices (e.g. medicine
ball or kettlebell) with rest periods of at least 1 min after
each exercise. The exercises follow the principle “as much
repetitions as possible”. The workload will be increased
from 4 × 2min to 4 × 3min to 4 × 4min according to the
performance level of the participants.
Passive control group
For ethical reasons, it is not justifiable to withhold the
exercise intervention completely from the passive con-
trol group. Therefore, the study controls will be included
in a waiting list to get offered the same exercise program
after T2 (Fig. 1).
Outcomes and assessments
Primary outcome
The primary aim of this study will be to examine the ef-
fect of a 12-week exercise intervention period on serum
concentrations of MMP-2 compared to control (see
Fig. 2). We hypothesize that the decrease in MMP-2 will
be greater in exercising MS patients compared with
control.
Blood samples will be taken by qualified technicians
via vein puncture from the antecubital vein in supine
position at T0 and T2 at the German Sport University
Cologne. Blood samples will be centrifuged at 3000 g for
10 min at 4 °C, and the supernatant will be stored at
− 40 °C until study completion. MMP-2 will be deter-
mined by enzyme-linked immune sorbent assay (ELISA)
(R&D Systems, Inc., Minneapolis, MN, USA) according to
the manufacturer’s instructions.
Secondary outcomes
Blood samples to determine chronic (T0 to T2) and
acute (T1,T1.1,T1.2) changes of biological secondary out-
comes, i.e. immune cell subsets and soluble (anti-) in-
flammatory factors, will be collected at the same time as
those of the primary outcome (see Fig. 2). Serum will be
stored at − 80 °C until analysis after study completion.
The assessment of physical and cognitive performance,
patient-reported outcomes, body composition and bio-
mechanical motion analysis will be done at T0 and T2.
Immune cell counts
Numbers and proportions of T cells (CD3+), T-helper
cells (CD3+CD4+), Th17 cells (CD3+CD4+CD161+CCR6+),
and regulatory T cells (CD3+CD4+CD25+CD127dim) will
be assessed at all time points (chronic (T0,T2) and acute
(T1,T1.1,T1.2)) and determined by using flow cytometry.
Gating strategies will be applied as reported by
Zimmer et al. and Wenning et al. [33, 34].
Soluble factors
Inflammatory (MMP-9, Tumor necrosis factor-alpha
(TNFα), Interferon gamma (IFNγ), Interleukin (IL)-6, IL-
17) and anti-inflammatory (IL-10) soluble factors as well
as TRP and metabolites (KYN, KYNA, QUIN, NAD+) will
be assessed at all time points. Serum MMP-2 will be
assessed at T1, T1.1 and T1.2 as well for investigating acute
serum changes after a single training session.
Serum levels of TRP, KYN, TNFα, IFNγ, IL-6, MMP-9,
IL-10 and IL-17 will be determined by using ELISA ac-
cording to manufactures instructions. Levels of KYNA
and QUIN will be assessed by high-performance liquid
chromatography. Further, enzymes involved into the TRP
degradation pathway and KYN metabolism (Kynurenin-3-
Monooxygenase, Indolamin-2,3-Dioxygenase, Kynurenin-
Aminotransferase) will be measured by real-time
quantitative PCR.
Serum levels of neurofilament light chain (NfL) will be
measured by the single-molecule enzyme-linked im-
munosorbent assay (ELISA) called single molecule array
(Simoa). That technology was shown to be 126- and 25-
fold more sensitive than regular ELISA or electrochemi-
luminescence, respectively [35]. Measurement will be
done as described previously by Disanto et al. [36].
Assessment of physical capacity
To assess body composition of the participants, bioelectrical
impedance analysis will be used and recorded according to
the manufacturer’s instructions. The calculated lean body
mass will be used as a stratification factor for randomization,
since visceral adipose tissue has been described to play a sig-
nificant role in inflammatory signalling [37] and therefore,
may impact biological outcome measures.
Cardiorespiratory fitness will be assessed on a cycle ergom-
eter (Ergoline®, Bitz, Germany) with a progressive cardiopul-
monary exercise test (CPET). Participants will begin the test
at an initial intensity of 30W (one-minute warm-up), in-
creasing by 15W every minute until volitional exhaustion.
This will be followed by a three-minute cool-down. The
resulting Wattmax at T0 will be used as a stratification factor
for randomization. The individual cardiorespiratory fitness
level will be monitored by direct and continuous measure-
ments (breath by breath) of VO2peak by ergospirometry
(Cortex, MetaLyzer 3B-R2, Germany). Blood lactate will be
measured before, immediately after and 3min after the
CPET via earlobe prick.
To assess muscular strength, a five-repetition maximum
(5RM) test will be conducted for lower (leg press) and
upper body compartments (chest press, lat pulldown).
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The American College of Sports Medicine (ACSM) guide-
lines will be applied to assess the 5RM [38]. These guide-
lines state that, firstly, the participants should warm up by
completing several submaximal repetitions. Secondly, the
5RM will be determined within four trials with rest
periods of 3min between trials. Thirdly, an initial weight
that is within the subject’s perceived capacity (~ 50–70%
of capacity) will be chosen. Thereafter, the resistance will
be progressively increased by 2.5-20 kg until the subject is
not able to complete the selected repetition(s). All
repetitions should be performed at the same speed of
movement and range of motion to ensure consistency
between trials. Lastly, the final weight lifted successfully as
the absolute 5RM will be recorded.
The rest periods between training sets will be decreased
to 2 min according to Miller [39] and Brown [40]. Follow-
ing instructions from Landers et al. [41], the hypothetical
one-repetition maximum (h1RM) will be calculated from
the 5RM test results. The calculated h1RM of the different
exercises are added together with the sum representing
Fig. 1 Flow diagram of this study. Baseline testing (T0) will be done before stratified randomization/allocation to either group. There will be a
further collection of blood samples 6 weeks after intervention onset (midpoint) at rest (T1), after resistance exercises (T1.1) and immediately after
the training session (T1.2) to investigate effects of acute training. Assessment of blood samples from the control group at T1 will be done at the
German Sport University Cologne without further measurements at T1.1 and T1.2. After the 12-week intervention period (T2), all outcome measures
will be assessed 48 h after the last training session to investigate effects of chronic training
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the outcome measure (h1RMsum) for muscular strength
and will be used as a stratification factor.
Motion capture
As maintenance of safe locomotion is important in the
course of MS, a biomechanical motion analysis using a
Vicon System (Vicon, Oxford, UK) and three-dimensional
force plates (Kistler, Winterthur, Schweiz) will be applied.
By using an inverse-dynamic model the mechanical power
on the ankle as well as the absorption and the release of
energy will be captured as parameters in addition to the
ground reaction forces.
Assessment of cognitive performance
To test the cognitive performance of the participants, the
Brief International Cognitive Assessment for Multiple
Fig. 2 Spirit diagram depicting the schedule of enrolment, interventions and assessments. T0 = baseline assessment before stratified
randomization; T1 = collection of blood samples immediately before a training session at midpoint (6 weeks after intervention onset). Biomarkers
at T1 will be further used for midpoint follow-up. Blood samples from the control group will be assessed at the German Sport University Cologne
without further measurements at T1.1 and T1.2; T1.1 = collection of blood samples after resistance exercises; T1.2 = collection of blood samples
immediately after the training session; T2 = assessment of outcomes 48 h after the last exercise session; * primary outcome; ** stratification factors:
i) Bioimpedance analysis using lean body mass; ii) Cardiovascular fitness using Wattmax; iii) Muscular strength using h1RMsum
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Sclerosis (BICAMS) battery [42] will be applied. The battery
comprises three tests to assess information processing
speed, verbal memory and visual memory which all consti-
tute major cognitive domains affected in the course of MS.
Information processing speed will be measured with
the Symbol Digit Modalities Test (SDMT). Digits from
one to nine are each paired with one of nine abstract
symbols, with a correct assignment being visible for the
participant throughout the testing. There is a pseudo-
randomized sequence of a total of 110 symbols on a
working sheet. After a training part of pairing ten sym-
bols is completed, the participant responds by saying the
corresponding digits of the remaining symbols as quickly
as possible. The indicator of performance is the total
number of correct symbol-digit pairs in 90 s.
Verbal memory will be measured with the California
Verbal Learning Test (CVLT) that shows good external
validity in MS [43]. The German version will be applied
according to Niemann et al. [44]. The test contains two
16-items word lists (list A, list B) of which just list A will
be used in this study. The list will be read out loud by
the investigator. Thereafter, the participant will be asked
to recall as many words as possible without any time
restriction. This procedure will be repeated in five con-
secutive trials. The indicator of performance is the total
number of words recalled during all trials.
Visual memory will be measured with the Brief Visuo-
spatial Memory Test-Revised (BVMT-R). Six abstract
geometric figures will be shown to the participant for 10
sec in three consecutive trials. After the presentation of
the visual stimulus figures, the participant will be asked
to draw, without any time restriction, as many recalled
figures as possible in the correct location, shape and
proportion. Each figure will be scored 0, 1, or 2 based on
the scoring criteria. The indicator of performance is the
total recall score in all three trials.
To exclude memory effects regarding verbal and visual
memory, parallel versions of the CVLT and BVMT-R
will be applied at T2.
Patient-reported outcomes
To assess physical activity behavior, both subjective and
objective measures will be applied three times (T0,T1,T2).
For subjective measurement, the Godin Leisure-Time
Exercise Questionnaire (GLTEQ) and the activity ques-
tionnaire will be used, respectively. The GLTEQ asks for
weekly frequencies of strenuous (9 points), moderate (5
points), and mild (3 points) activities with all points
being multiplied by the number of weekly conductance.
Reference score units are ≥24 (≙ active), 14 to 23
(≙ moderately active) and < 14 (≙ insufficiently active) [45].
The second activity questionnaire is asking for the
activity of the patients during the last 1, 6 and 12 weeks
using either i) boxes to provide exact time of physical
activity (in hours) and exercise (in minutes) during the
last week and ii) visual analogue scales ranging from
“low activity” to “high activity” to assess physical activity
in the last 1, 6 and 12 weeks.
For objective measurement, an actimetry sensor (Acti-
Graph GT9X Link) is applied to each participant for seven
consecutive days in order to identify differences in rest and
activity cycles. The sensor will be attached to the hip to bet-
ter monitor the activity level. There will be several interest-
ing outcome measures with moderate to vigorous physical
activity (MVPA) being the main outcome measure.
Fatigue will be assessed with the two-dimensional Fatigue
Scale for Motor and Cognitive functions (FSMC). The
FSMC has defined cut-off scores to differentiate between
mildly (≥43 sum score), moderately (≥53 sum score) and
severely (≥63 sum score) fatigued patients using 20 items
with ten items for each dimension [46]. The German
version shows excellent test-retest reliability [47].
Depression and anxiety will be measured with the
German version of the Center for Epidemiologic Studies
Depression Scale (CES-D) [48, 49]. In a 20-item measure
using a four-point Likert scale, the participants will be
asked to rate how often they experienced symptoms
associated with depression over the past one to 2 weeks.
Health-related quality of life will be evaluated with the
Multiple Sclerosis International Quality of Life Question-
naire (MusiQol) by describing nine dimensions with 31
items [50]. The German version shows good test-retest
reliability [51].
Sleeping quality will be assessed by the German ver-
sion of the Pittsburgh Sleep Quality Index (PSQI) [52].
Participants rate their subjective sleep quality, sleep la-
tency, sleep duration, habitual sleep efficiency, sleep dis-
turbances, use of sleeping medication, and daytime
sleepiness over the past 4 weeks.
Social integration will be assessed with the German ver-
sion of a social integration index according to Bittner
et al. [53]. The index contains three domains, each scored
from 0 to 2 (total range of index from 0 to 6) [54]. Level I
of the index includes persons who scored 0 or 1. Further
levels are II (range 2–3), III (range 4–5), and IV (6). The
index includes three types of ties: 1) marital status or co-
habitation, 2) contacts with close friends and family, and
3) affiliation with voluntary associations. Marital status
will be scored 0 if the subject is single/divorced/widowed
and 2 if the subject is married/living with a partner. Re-
garding contacts, subjects are given a score of 0 (0–2 con-
tacts), 1 (3–11 contacts), or 2 (≥12 contacts). The
affiliation with voluntary associations be calculated by
positive responses to questions on membership in any of
six types of political, religious, community, sports, or
professional organizations.
All questionnaire-based patient-reported outcomes
will be assessed using a tablet computer (iPad, 128GB
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Version 2018). For this purpose, Qualtrics Research
Core software will be applied.
Data management
In order to monitor participant adherence to the weekly
training sessions, a training sheet will be implemented
that will i) show whether intervention group participants
took part in the planned training sessions and ii) be used
to document training progression. Participants will be
contacted by email or phone if they fail to take part in
two consecutive training sessions.
Additionally, as a safeguard for any potential data loss,
all study data will be stored in a password-protected
computer device that is not connected to the internet.
Additionally, training documentation data of each
participant will be entered in the computer device on a
weekly basis to provide fast and easy access to training
adherence and training progression.
Data analysis
Statistical analyses will be performed by a statistician
blinded to treatment groups. Level of significance is set at
p ≤ 0.05. All values will be presented in means ± standard
deviation. Statistical analyses will be conducted using the
actual SPSS Version® (IBM®, Armonk, NY, USA) and R.
The required sample size to evaluate the between-group
effect of the intervention on the primary outcome (serum
changes of MMP-2 from baseline (T0) to post (T2)) in an
analysis of covariance model (ANCOVA) was estimated
using G*Power 3.1.9.2 [55]. Serum concentration of
MMP-2 at baseline (T0) will be used as covariate. Based
on already published study results [20], a medium to large
effect size (Cohens d = 0.6) was used for sample size calcu-
lation. Statistical significance will be set 5% with statistical
power (1-β) of 0.8. The sample size was calculated accord-
ing to the formula N = (1-r2)*n described by Borm et al.
[56]. The correlation was conservatively set at r = 0.6
which results in a preliminary sample size of N = 58. The
expected drop-out rate is 15%. Therefore, a total of 64
participants will be recruited.
Primary analysis
An intention-to-treat analysis will be conducted. To in-
vestigate the effect of the intervention (12-week exercise
intervention of combined functional resistance and en-
durance exercise) compared to control on the primary
outcome MMP-2, we will conduct a 2 (intervention
group vs. control group) × 2 (T0 vs. T2) analysis of co-
variance (ANCOVA). This model will be adjusted for
baseline values and lean body mass at T0. As measure of
effect size partial Eta-squared and Cohen’s d values,
respectively, will be calculated.
Secondary analysis
An intention-to-treat analysis will be conducted. To inves-
tigate the effect of the intervention compared to control
on secondary outcomes, a baseline-adjusted 2 (interven-
tion group vs. control group) × 2 (T0 vs. T2) ANCOVA
model will be applied. To determine if groups differ at T1
and/or at T2, simple effects analyses (Bonferroni corrected)
will be performed.
As measure of effect size partial Eta-squared and
Cohen’s d values, respectively, will be calculated. Bivari-
ate correlation analyses (Pearson) will be conducted to
determine potential associations between changes in bio-
markers and physical performance outcomes, cognitive
performance and/or patient-reported outcomes from T0
to T2 (delta T2-T0).
To investigate the effect of an acute training session
on biological markers in intervention group participants,
we will conduct a repeated measures ANOVA at T1
(baseline), T1.1 (during) and T1.2 (post) exercise session.
Safety
To ensure safety during each training session, exercise
intensity will be monitored both objectively and subject-
ively based on the participants heart rate (measured by
Polar FS1C) and their rating of perceived exertion (RPE,
Borg scale (6-20)), respectively. Further, there will be a
training sheet that will be filled in by the participants
during each training session to monitor adequate
training progression and intensity. The MS experienced
exercise scientist who will conduct the training will con-
tribute substantially to the safety of each participant as
well. All trainers are able to administer first aid.
All severe adverse events – that include i) severe
cardiovascular and pulmonary diseases (e.g. renal failure,
hepatic dysfunction, cardiovascular disease) and ii)
severe cardiovascular exacerbations (e.g. RR > 240/120)
during a training session will be directly reported to the
ethical committee.
The drop-out rate will be recorded in total and
separately for each group.
Discussion
Disability in pwMS often continues to worsen despite
immunotherapy, so alternative and/or adjunct treat-
ments seem imperative for this patient cohort [1]. Be-
sides the need of encouraging pwMS to engage more in
moderate to vigorous exercise [6], existing (multimodal)
therapeutic exercise regimens need to be continuously
optimized in order to decrease the socioeconomic conse-
quences of MS and to improve the quality of life of
pwMS. In this study only persons with a relatively low
disease severity (EDSS 0–4) will be included. Due to the
fact that the disease-specific symptomatology is limited
only to a few systems, the probability to include
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participants in an early disease state is increased. That in
turn allows to take advantage of a proposed “window of
opportunity” that may be a promising approach to
effectively slow down disease progression [29].
Moreover, the approach of this study, i.e. community-
based training with combined functional resistance and
endurance exercises in a publicly available fitness center,
may have profound impact on general feasibility of
effective exercise treatments and optimization of existing
exercise recommendations.
Improving the BBB integrity by reducing MMP-2
serum concentration as the primary outcome of this
study and to establish immune homeostasis seem to be
an integral component for decreasing both MS-specific
symptomology and disease progression.
Another important objective of this study is to test as-
sumptions of existing hypothetical biopsychosocial models
in pwMS [9, 10] in the context of exercise neuroimmuno-
logy by correlating the assessed cognitive capacity and
patient-reported outcomes like anxiety/depression and
fatigue with immune-related biomarkers and cell popula-
tions. Moreover, the assessment of the acute effect will
extend knowledge of acute exercise-induced effects on
immune signaling, proportions on immune cell subsets
and the kynurenine pathway in persons with RRMS.
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